Ramsay share price plunges 4% after suitor withdraws takeover offer

A handy exit for investors of the private hospital provider has now disappeared. What now?

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After copping a pretty ordinary financial report in the morning, Ramsay Health Care Limited (ASX: RHC) shareholders have more to worry about Friday afternoon.

The healthcare shares were put in a trading halt in the morning but were released at 1:32pm after the company updated the ASX on KKR & Co consortium's takeover proposal.

The letter received overnight indicated the consortium is withdrawing from the $88 per share offer first floated in April.

At the time of writing, Ramsay shares have fallen 4% to $70.02.

How do you handle a problem like Ramsay Santé?

The cancellation of the takeover offer comes after the consortium ran into difficulties performing due diligence on Ramsay's European subsidiary Ramsay Generale De Sante SA (EPA: GDS).

Ramsay Health owns about 53% of the shares in the listed company commonly known as Ramsay Santé. Ramsay chief Craig McNally is chair of the European arm.

The trouble is Ramsay Santé did not want to open up its books to KKR & Co, because it owns its French rival Elsan.

The stalemate had gone on for the last four months, but now it seems the consortium has run out of patience.

"The Consortium has advised Ramsay that it has elected to no longer seek due diligence access from Ramsay Santé and has advised the board of Ramsay Santé accordingly," Ramsay stated to the ASX on Friday afternoon.

"Ramsay Santé due diligence was required to progress the indicative proposal and the Consortium has now informed Ramsay that it has withdrawn the indicative proposal."

Could there be a third offer?

Due to the difficulties with Ramsay Santé, the consortium had already put up an alternative offer where the first 5,000 shares for each shareholder would receive $88. Then for each stock above that the investor would receive $78.20 plus 0.22 Ramsay Santé shares.

Perhaps anticipating the consortium's rejection of the original $88 offer, on Thursday night the Ramsay board stated the alternative proposal was not acceptable.

"The Ramsay Board has considered the alternative proposal and is unanimously of the view that it is meaningfully inferior to the consortium's indicative proposal of $88.00 cash per share," the company stated.

"In forming this view, the Ramsay board had regard to both the lower implied value relative to the allcash proposal, as well as structural challenges, execution complexity and the low liquidity of Ramsay Santé shares."

So the original proposal has been killed by the buyer and the alternative offer was ruled out by Ramsay.

This might not be the end of the story though.

The healthcare provider announced on Friday afternoon that it would still keep the door open for a different, third, offer.

"Ramsay is prepared to engage with the consortium to determine whether it can put forward an improved binding proposal that is capable of recommendation by the Ramsay board."

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »